Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 8Myeloid 7Classical hematology 4Tumor-Agnostic 3Other solid neoplasm 3Lymphoid 3Gastrointestinal 3Head & Neck 2Thoracic 1Plasma cell 1Other neoplasm 1Gynecologic 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Squamous Cell 1Carcinoma, Hepatocellular 1Anus Neoplasms 1

Interventions

Oxaliplatin 1413Fluorouracil 1301Capecitabine 1087Gemcitabine 1045Leucovorin 932Irinotecan 818Bevacizumab 804Cisplatin 669Radiotherapy 536Cetuximab 470pembrolizumab 428Paclitaxel 390Nivolumab 337130-nm albumin-bound paclitaxel 325Drug Therapy 314Docetaxel 287S 1 (combination) 274Sorafenib 266Folfox protocol 261Albumin-Bound Paclitaxel 259sintilimab 211durvalumab 210Surgical Procedures, Operative 204tislelizumab 203Radiosurgery 202lenvatinib 201apatinib 200Carboplatin 187Magnetic Resonance Spectroscopy 183regorafenib 181

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × ON 01910 × Gastrointestinal × Clear all
NCT01807546 2017-06-26

Oral Rigosertib for Squamous Cell Carcinoma

Traws Pharma, Inc.

Phase 2 Completed
64 enrolled
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Anus Neoplasms, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00861783 2017-06-23

Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma

Traws Pharma, Inc.

Phase 1 Completed
16 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT01360853 2016-08-04

ONTRAC

Traws Pharma, Inc.

Phase 3 Completed
160 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡